please find enclosed
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech's board approved unaudited Q3FY26 results on Feb 13, 2026, reviewed by auditor P. Murali & Co. with an unqualified review report. Standalone revenue from operations grew 9.4% YoY to Rs. 1,336.60 lakh in Q3, while 9M revenue rose 12.9% to Rs. 3,880.12 lakh against Rs. 3,438.18 lakh a year ago. Standalone net profit for Q3 jumped 40.7% YoY to Rs. 125.83 lakh (from Rs. 89.43 lakh), but 9M PAT fell sharply to Rs. 350.08 lakh versus Rs. 638.49 lakh earlier, largely because prior-year 9M included Rs. 465.18 lakh of other income versus only Rs. 41.04 lakh this year. Consolidated results were broadly similar, with Q3 PAT at Rs. 124.81 lakh and 9M PAT at Rs. 345.38 lakh. Total expenses rose due to higher employee costs, depreciation, and traded goods purchases, while finance costs eased.
Q3 shows solid revenue and PAT growth on both standalone and consolidated basis, but the sharp 9M PAT drop (driven by lower other income and rising operating costs compressing margins) may temper near-term investor enthusiasm. Watch margin trajectory and H1 weakness — the full-year picture looks softer than the quarterly uptick suggests.